T Cell Specific Surface Glycoprotein CD28 TP44 or CD28 Pipeline Review, H2 2018
Summary
T Cell Specific Surface Glycoprotein CD28 TP44 or CD28 CD28 is a proteins expressed on T cells. It costimulates signals required for T cell activation and survival. It enhances the production of IL4 and IL10 in Tcells in conjunction with TCR/CD3 ligation and CD40L costimulation.
T Cell Specific Surface Glycoprotein CD28 TP44 or CD28 pipeline Target constitutes close to 8 molecules. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 5 respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Infectious Disease, Musculoskeletal Disorders, Ophthalmology and Toxicology which include indications Rheumatoid Arthritis, Graft Versus Host Disease GVHD, Multiple Sclerosis, Solid Tumor, Acute Renal Failure ARF Acute Kidney Injury, BCell Chronic Lymphocytic Leukemia, Gastrointestinal Radiation Toxicity, Kidney Transplant Rejection, Plaque Psoriasis Psoriasis Vulgaris, Psoriasis, Psoriatic Arthritis, Sepsis, Skin And Soft Tissue Infections, Stem Cell Transplantation and Uveitis.
The latest report T Cell Specific Surface Glycoprotein CD28 TP44 or CD28 Pipeline Review, H2 2018, outlays comprehensive information on the T Cell Specific Surface Glycoprotein CD28 TP44 or CD28 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in T Cell Specific Surface Glycoprotein CD28 TP44 or CD28 targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for T Cell Specific Surface Glycoprotein CD28 TP44 or CD28
The report reviews T Cell Specific Surface Glycoprotein CD28 TP44 or CD28 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in T Cell Specific Surface Glycoprotein CD28 TP44 or CD28 targeted therapeutics and enlists all their major and minor projects
The report assesses T Cell Specific Surface Glycoprotein CD28 TP44 or CD28 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to T Cell Specific Surface Glycoprotein CD28 TP44 or CD28 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for T Cell Specific Surface Glycoprotein CD28 TP44 or CD28
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding T Cell Specific Surface Glycoprotein CD28 TP44 or CD28 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope